Syndromic Multiplex Diagnostics Markets: Market Forecast, Competitive Landscape, Company Revenue Estimates, Technology and Policy Outlook, 2027-2031

Table of Contents

List of Tables

List of Figures

1. Executive Summary

• 1.1 Situation Analysis
• 1.2 Market Snapshot
• 1.3 Key Findings
• 1.4 Investment & Strategic Thesis

2. Research Methodology & Scope

• 2.1 Scope & Market Definition
• 2.2 Value Basis
• 2.3 Market Segments
• 2.4 Geographic Coverage
• 2.5 Overlap with Sister Reports
• 2.6 Methodology
• 2.7 Sources
• 2.8 Author
• 2.9 Limitations

3. Introduction to Syndromic Testing

• 3.1 What is Syndromic Testing?
• 3.2 The Clinical Case: Speed, Breadth, Stewardship and Length of Stay
• 3.3 The Evidence and the Over-Testing Critique
• 3.4 From Luminex xTAG and BioFire to Today
• 3.5 The Industry and Its Players

4. The Global Market for Syndromic Multiplex Diagnostics

• 4.1 Global Market Overview by Country
• 4.2 Global Market by Syndrome – Overview
• 4.3 Global Market by Panel Size – Overview
• 4.4 Global Market by Technology – Overview
• 4.5 Global Market by Setting – Overview
• 4.6 Global Market by Product – Overview

5. Respiratory & Pneumonia Panels

• 5.1 Upper Respiratory Panels After the Pandemic
• 5.2 Mid-Size versus Comprehensive Panels
• 5.3 The Main Respiratory and Pneumonia Panels
• 5.4 Pneumonia and Lower Respiratory Panels
• 5.5 Payer Limits and the Outlook

6. Gastrointestinal, Meningitis & Encephalitis Panels

• 6.1 Beyond the Respiratory Season
• 6.2 Gastrointestinal Panels: From Stool Culture to Syndromic PCR
• 6.3 A Crowded Field: The 2026 Wave of GI Launches
• 6.4 Meningitis and Encephalitis Panels
• 6.5 Evidence and the False-Positive Debate
• 6.6 Outlook for GI and ME Panels

7. Bloodstream, STI & Other Panels

• 7.1 Three Smaller Markets with Faster Growth
• 7.2 Positive Blood Culture Identification
• 7.3 STI, Vaginitis and Urogenital Panels
• 7.4 Joint, Wound, Tropical Fever and Special Pathogen Panels
• 7.5 Outlook

8. Panel Size, Flexible Panels & Reimbursement Economics

• 8.1 Why Panel Size Matters
• 8.2 MolDX Coverage Rules and the 2026 Revisions
• 8.3 Medicare Pricing, the 2027 Fee Schedule and Commercial Payers
• 8.4 Flexible and Pay-per-Target Panels
• 8.5 Reimbursement in Europe and Japan
• 8.6 Panel Economics for Laboratories

9. Technology Landscape

• 9.1 How Syndromic Panels Work
• 9.2 Sample-to-Answer PCR Systems
• 9.3 Batch Laboratory Multiplex PCR
• 9.4 Syndromic NGS and Metagenomics
• 9.5 Point-of-Care Syndromic Testing
• 9.6 Emerging Methods, Connectivity, Software and AI

10. Regulation, Reimbursement & Policy

• 10.1 The US Regulatory Framework for Syndromic Panels
• 10.2 Laboratory-Developed Tests and Syndromic NGS
• 10.3 US Reimbursement: CPT Codes, CLFS and MolDX
• 10.4 Europe: The IVDR
• 10.5 China and Japan

11. China, Asia-Pacific & Emerging Markets

• 11.1 Regional Overview
• 11.2 China
• 11.3 Japan and South Korea
• 11.4 India, Southeast Asia and Australia
• 11.5 Latin America, Middle East and Africa
• 11.6 Outlook

12. Recent Developments

• 12.1 Recent Developments – Importance and How to Use This Section
• 12.2 QIAGEN Agrees to Be Taken Private by EQT
• 12.3 bioMerieux H1 2026: BIOFIRE Respiratory Panels Fall 17%, SPOTFIRE Grows, Targets Cut
• 12.4 FDA Clears Cepheid's 13-Pathogen Xpert Respiratory Panel
• 12.5 FDA Clears Cepheid's Xpert GI Panel
• 12.6 FDA Clears QIAstat-Dx Blood Culture Panels for Gram-Positive, Fungal and Gram-Negative Pathogens
• 12.7 FDA Grants 510(k) Clearance and CLIA Waiver for BIOFIRE SPOTFIRE Vaginitis Panel
• 12.8 FDA Clears DiaSorin LIAISON PLEX GI Flex Assay
• 12.9 Roche Launches cobas eplex Respiratory Pathogen Panel 3 in CE Markets
• 12.10 Quest Diagnostics Adopts LIAISON PLEX
• 12.11 MolDX Revises Syndromic Panel Billing Article A58720 and Eases the Ordering-Provider Rule

13. Operations, Manufacturing & Supply Chain

• 13.1 How Syndromic Panels Are Made
• 13.2 Capacity, Automation and the BIOFIRE Expansion
• 13.3 Seasonality, Inventory and the Respiratory Reset
• 13.4 Critical Inputs, Tariffs and Sourcing Risk
• 13.5 Regulatory Operations, Service and Installed-Base Economics

14. Competitive Landscape

• 14.1 Market Structure
• 14.2 Tiers of Suppliers
• 14.3 Leaders by Syndrome and Setting
• 14.4 Sequencing, Point-of-Care and Emerging Players
• 14.5 Consolidation and Ownership Change
• 14.6 Outlook

15. SWOT, Porter's Five Forces & Investment Risk Analysis

• 15.1 SWOT Analysis
• 15.2 Porter's Five Forces
• 15.3 Investment Risk Analysis

16. Strategic Recommendations

• 16.1 Executives, Marketing, Sales and Business Development
• 16.2 Consultants and Investment Advisors

17. Market Forecast by Syndrome, 2026–2031

• 17.1 Upper Respiratory
• 17.2 Pneumonia & Lower Respiratory
• 17.3 Gastrointestinal
• 17.4 Bloodstream & Sepsis
• 17.5 Meningitis & Encephalitis
• 17.6 STI & Urogenital
• 17.7 Joint, Wound & Other

18. Market Forecast by Panel Size, 2026–2031

• 18.1 Targeted (4-10 Targets)
• 18.2 Mid-Size (11-25 Targets)
• 18.3 Comprehensive (26+ Targets)
• 18.4 Selectable & Pay-per-Target

19. Market Forecast by Technology, 2026–2031

• 19.1 Sample-to-Answer PCR
• 19.2 Batch Lab Multiplex PCR
• 19.3 Syndromic NGS & Metagenomics
• 19.4 Other Technology

20. Market Forecast by Setting, 2026–2031

• 20.1 Hospital Lab
• 20.2 Reference & Outpatient Lab
• 20.3 Point of Care
• 20.4 Public Health & Other

21. Market Forecast by Product, 2026–2031

• 21.1 Instruments
• 21.2 Panels & Cartridges
• 21.3 Other Reagents
• 21.4 Software & Services

22. Company Profiles

• 22.1 Abbott Laboratories
• 22.2 Altona Diagnostics
• 22.3 Applied BioCode
• 22.4 Aptitude Medical Systems
• 22.5 AusDiagnostics
• 22.6 BGI Genomics
• 22.7 bioMerieux
• 22.8 Bio-Rad Laboratories
• 22.9 Bosch Healthcare Solutions (Vivalytic)
• 22.10 Cepheid (Danaher)
• 22.11 Credo Diagnostics Biomedical
• 22.12 Daan Gene
• 22.13 Delve Bio
• 22.14 DiaSorin (Luminex)
• 22.15 Fluxergy
• 22.16 Genetic Signatures
• 22.17 Hologic
• 22.18 Illumina
• 22.19 Jiangsu Bioperfectus Technologies
• 22.20 Karius
• 22.21 Meridian Bioscience
• 22.22 Molbio Diagnostics
• 22.23 Novacyt (Primerdesign)
• 22.24 Oxford Nanopore Technologies
• 22.25 Qiagen
• 22.26 QuidelOrtho
• 22.27 R-Biopharm
• 22.28 Roche Diagnostics
• 22.29 Sansure Biotech
• 22.30 Seegene
• 22.31 Siemens Healthineers
• 22.32 SpeeDx
• 22.33 Thermo Fisher Scientific
• 22.34 Vela Diagnostics
• 22.35 Visby Medical
• 22.36 Waters Corporation (formerly BD Diagnostic Solutions)

23. Appendix

• 23.1 Abbreviations
• 23.2 Developments Archive
• 23.3 Report Limitations Restated

List of Tables

• Table 1 Key Market Indicators (constant 2026 US$)
• Table 2 Global Market by Segment, 2026 and 2031 (US$ millions, constant 2026 dollars)
• Table 3 Definitions of the 23 Market Segment Lines
• Table 4 The 14 Countries and Regions Forecast in This Report
• Table 5 Overlap with Other Howe Sound Research Reports
• Table 6 Main Syndromes Covered by Multiplex Panels
• Table 7 Milestones in Syndromic Testing
• Table 8 Global Market by Country
• Table 9 Global Market by Syndrome
• Table 10 Global Market by Panel Size
• Table 11 Global Market by Technology
• Table 12 Global Market by Setting
• Table 13 Global Market by Product
• Table 14 Main Respiratory and Pneumonia Syndromic Panels, October 2026
• Table 15 Gastrointestinal and Meningitis & Encephalitis Segments, 2026 and 2031
• Table 16 Leading Gastrointestinal Syndromic Panels
• Table 17 Leading Meningitis & Encephalitis Tests
• Table 18 Bloodstream, STI and Other Segments, 2026 and 2031
• Table 19 Leading Bloodstream Infection Syndromic Tests
• Table 20 Leading Vaginitis and STI Syndromic Panels
• Table 21 Joint, Wound and Special Pathogen Panels
• Table 22 Syndromic Panel Market by Panel Size, 2026 and 2031
• Table 23 Main Coverage Conditions in the MolDX Syndromic Panel LCD (October 2026)
• Table 24 Selected Flexible, Mini and Mid Panels
• Table 25 How Panel Size Affects Laboratory Economics
• Table 26 Main Technologies for Syndromic Testing
• Table 27 Syndromic Panel Market by Technology, 2026 and 2031
• Table 28 Key Regulatory and Policy Dates for Syndromic Multiplex Diagnostics
• Table 29 Regulation and Reimbursement of Syndromic Panels by Region
• Table 30 Syndromic Multiplex Diagnostics in Asia-Pacific and Emerging Markets, 2026 and 2031 (US$ millions)
• Table 31 Leading Domestic Syndromic Testing Suppliers in China
• Table 32 Recent Developments in This Edition, Summary
• Table 33 Manufacturing Profile of Syndromic Diagnostic Products
• Table 34 Critical Inputs for Syndromic Multiplex Diagnostics
• Table 35 Syndromic Multiplex Diagnostics Market by Product, 2026 and 2031
• Table 36 Competitive Structure by Technology
• Table 37 Tiers of Syndromic Multiplex Diagnostics Suppliers
• Table 38 Tier 2 Sample-to-Answer Challengers
• Table 39 Leading Products by Syndrome
• Table 40 SWOT Analysis – Strengths and Weaknesses
• Table 41 SWOT Analysis – Opportunities and Threats
• Table 42 Porter's Five Forces Ratings
• Table 43 Investment Risk Matrix
• Table 44 Selected Growth and Value Opportunities
• Table 45 Upper Respiratory by Country
• Table 46 Pneumonia & Lower Respiratory by Country
• Table 47 Gastrointestinal by Country
• Table 48 Bloodstream & Sepsis by Country
• Table 49 Meningitis & Encephalitis by Country
• Table 50 STI & Urogenital by Country
• Table 51 Joint, Wound & Other by Country
• Table 52 Targeted (4-10 Targets) by Country
• Table 53 Mid-Size (11-25 Targets) by Country
• Table 54 Comprehensive (26+ Targets) by Country
• Table 55 Selectable & Pay-per-Target by Country
• Table 56 Sample-to-Answer PCR by Country
• Table 57 Batch Lab Multiplex PCR by Country
• Table 58 Syndromic NGS & Metagenomics by Country
• Table 59 Other Technology by Country
• Table 60 Hospital Lab by Country
• Table 61 Reference & Outpatient Lab by Country
• Table 62 Point of Care by Country
• Table 63 Public Health & Other by Country
• Table 64 Instruments by Country
• Table 65 Panels & Cartridges by Country
• Table 66 Other Reagents by Country
• Table 67 Software & Services by Country

List of Figures

• Figure 1 Key Graphic – Syndromic Testing Moves to the Bedside: Syndromic Multiplex Diagnostics Market by Setting, 2026 vs 2031
• Figure 2 Global Market Pareto Chart
• Figure 3 Global Market by Syndrome - Base vs. Final
• Figure 4 Global Market by Syndrome Base Year
• Figure 5 Global Market by Syndrome End Year
• Figure 6 Syndrome Share by Year
• Figure 7 Syndrome Segments Growth
• Figure 8 Global Market by Panel Size - Base vs. Final
• Figure 9 Global Market by Panel Size Base Year
• Figure 10 Global Market by Panel Size End Year
• Figure 11 Panel Size Share by Year
• Figure 12 Panel Size Segments Growth
• Figure 13 Global Market by Technology - Base vs. Final
• Figure 14 Global Market by Technology Base Year
• Figure 15 Global Market by Technology End Year
• Figure 16 Technology Share by Year
• Figure 17 Technology Segments Growth
• Figure 18 Global Market by Setting - Base vs. Final
• Figure 19 Global Market by Setting Base Year
• Figure 20 Global Market by Setting End Year
• Figure 21 Setting Share by Year
• Figure 22 Setting Segments Growth
• Figure 23 Global Market by Product - Base vs. Final
• Figure 24 Global Market by Product Base Year
• Figure 25 Global Market by Product End Year
• Figure 26 Product Share by Year
• Figure 27 Product Segments Growth
• Figure 28 Upper Respiratory Growth
• Figure 29 Pneumonia & Lower Respiratory Growth
• Figure 30 Gastrointestinal Growth
• Figure 31 Bloodstream & Sepsis Growth
• Figure 32 Meningitis & Encephalitis Growth
• Figure 33 STI & Urogenital Growth
• Figure 34 Joint, Wound & Other Growth
• Figure 35 Targeted (4-10 Targets) Growth
• Figure 36 Mid-Size (11-25 Targets) Growth
• Figure 37 Comprehensive (26+ Targets) Growth
• Figure 38 Selectable & Pay-per-Target Growth
• Figure 39 Sample-to-Answer PCR Growth
• Figure 40 Batch Lab Multiplex PCR Growth
• Figure 41 Syndromic NGS & Metagenomics Growth
• Figure 42 Other Technology Growth
• Figure 43 Hospital Lab Growth
• Figure 44 Reference & Outpatient Lab Growth
• Figure 45 Point of Care Growth
• Figure 46 Public Health & Other Growth
• Figure 47 Instruments Growth
• Figure 48 Panels & Cartridges Growth
• Figure 49 Other Reagents Growth
• Figure 50 Software & Services Growth